Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS)
Cancer · 15.05.2024 · 130 (10) · 1797-1806
DOI: 10.1002/cncr.35190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 22.01.2024. Verfasst von Jinping Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine and Public Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: U.S. Department of Defense, American Cancer Society.
Abstract (Originalsprache)
Background
Active surveillance (AS) is the preferred strategy for low‐risk prostate cancer (LRPC); however, limited data on determinants of AS adoption exist, particularly among Black men.
Methods
Black and White newly diagnosed (from January 2014 through June 2017) patients with LRPC ≤75 years of age were identified through metro‐Detroit and Georgia population‐based cancer registries and completed a survey evaluating factors influencing AS uptake.
Results
Among 1688 study participants, 57% chose AS (51% of Black participants, 61% of White) over definitive treatment. In the unadjusted analysis, patient factors associated with initial AS uptake included older age, White race, and higher education. However, after adjusting for covariates, none of these factors was significant predictors of AS uptake. The strongest determinant of AS uptake was the AS recommendation by a urologist (adjusted prevalence ratio, 6.59, 95% CI, 4.84–8.97). Other factors associated with the decision to undergo AS included a shared patient–physician treatment decision, greater prostate cancer knowledge, and residence in metro‐Detroit compared with Georgia. Conversely, men whose decision was strongly influenced by the desire to achieve “cure” or “live longer” with treatment and those who perceived their LRPC diagnosis as more serious were less likely to choose AS.
Conclusions
In this contemporary sample, the majority of patients with newly diagnosed LRPC chose AS. Although the input from their urologists was highly influential, several patient decisional and psychological factors were independently associated with AS uptake. These data shed new light on potentially modifiable factors that can help further increase AS uptake among patients with LRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Family Medicine and Public Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Urology, School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Epidemiology, School of Public Health, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Jinping Xu, Cathryn H Bock, Kevin Ginsburg
Förderung
- U.S. Department of Defense
- American Cancer Society
Zitieren
APA
Xu, J., Bock, C. H., Janisse, J., Woo, J., Cher, M. L., Ginsburg, K., Yacoub, R., & Goodman, M. (2024). Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS). Cancer, 130(10), 1797-1806. https://doi.org/10.1002/cncr.35190
Vancouver
Xu J, Bock CH, Janisse J, Woo J, Cher ML, Ginsburg K, et al. Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS). Cancer. 2024;130(10):1797-1806. doi:10.1002/cncr.35190
BibTeX
@article{Xu2024,
author = {Xu, Jinping and Bock, Cathryn H and Janisse, James and Woo, Justin and Cher, Michael L and Ginsburg, Kevin and Yacoub, Rami and Goodman, Michael},
title = {Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS)},
journal = {Cancer},
year = {2024},
volume = {130},
number = {10},
pages = {1797--1806},
doi = {10.1002/cncr.35190}
}
EUVIMED